

CONTENTS

LIST OF CONTRIBUTORS	xv
1. SEPARATION AND PURIFICATION OF TOXINS FROM SNAKE VENOMS	1
R. C. Hider, Evert Karlsson, and Sholeh Namiranian	
*1. Introduction	1
1.1. Enzymes (Molecular Weight 150,000–13,000)	1
1.2. Polypeptide Toxins (Molecular Weight 10,000–5000)	2
1.3. Low-Molecular-Weight Components (Molecular Weight <1500)	3
2. Purification Methods	3
2.1. General Concepts	3
2.2. Lyophilization of Toxins	5
3. Gel Filtration	5
3.1. Basic Principles	5
3.2. Common Gel Filtration Media	6
3.3. Choice of Gel	6
3.4. Choice of Buffers	7
3.5. Desalting and Estimation of Protein Concentration	9
3.6. Estimation of Molecular Weights	9
3.7. Protein Adsorption	10
3.8. Packing of Columns	10
3.9. Column Dimensions, Sample Size, and Flow Rate	11
3.10. Cleaning and Storage of Chromatography Media	11
3.11. High-Pressure Liquid Chromatography	12
4. Ion-Exchange Chromatography	12
4.1. Basic Principles	12
4.2. Elution Techniques	14
4.2.1. Stepwise elution	15
4.2.2. Gradient elution	15
4.3. Ion Exchangers	16
4.3.1. Nonporous hydrophobic matrices	17
4.3.2. Macroporous hydrophilic matrices	19
4.4. Porosity and Capacity of Matrix	21
4.5. Buffers for Ion-Exchange Chromatography	21
4.6. Selection of Conditions	22
4.7. High-Pressure Liquid Chromatography	23
4.8. Potential Problems with Ion-Exchange Chromatography	25
4.9. Cleaning and Storage of Ion Exchangers	26
5. Hydrophobic Interaction Chromatography	26
5.1. Basic Principles	26
5.2. Purification of Toxins	29
5.2.1. Elapid cardiotoxins	29
5.2.2. Neurotoxins	30
References	31

2. IMMUNOLOGY OF SNAKE TOXINS	35
André Ménez	
1. Introduction	35
2. Definitions	35
3. Curaremimetic Toxins	36
3.1. Some Immunological Properties of Curaremimetic Toxins	38
3.2. Attempts to Identify Amino Acids Determining Antigenicity in Curaremimetic Toxins, Using Polyclonal Antibodies	38
3.2.1. Cross-reactivity studies using natural toxin variants	38
3.2.2. Cross-reactivity studies using chemically modified derivatives	39
3.2.3. Cross-reactivity studies using protein fragments	40
3.2.4. On the heterogeneity of polyclonal antibodies	41
3.3. Mapping of Epitopes of Curaremimetic Toxins Using Monoclonal Antibodies	41
3.4. Neutralizing Capacities of Curaremimetic Toxin-Specific Antibodies	47
3.5. On the Molecular Mechanisms of Neutralization of a Curaremimetic Toxin	51
3.6. Antibodies to Synthetic Peptides Mimicking Curaremimetic Toxins	53
3.7. Antibodies to Recombinant Curaremimetic Toxins	56
✱ 4. Cardiotoxins (Cytotoxins)	57
5. Proteins with Phospholipase A ₂ Structure (PLA ₂)	61
5.1. Presynaptically Acting Toxins	62
5.1.1. Taipoxin	62
5.1.2. β -Bungarotoxin	63
5.1.3. Notexin	64
5.1.4. Crotoxin	66
5.1.5. Mojave toxin	68
5.2. Other PLA ₂	68
6. Facilitatory Toxins: Dendrotoxins	69
7. Other Snake Venom Components	70
7.1. Myotoxins	70
7.2. Hemorrhagic Factors	72
7.3. Factor X Activator	72
7.4. Nerve Growth Factor	73
7.5. Hyaluronidase	73
8. Antivenoms, Venom, and Toxin Detection	73
9. Neutralization of Venoms by Factors Other Than Antivenoms	75
10. Conclusions	76
References	78
3. PHOSPHOLIPASES IN SNAKE VENOMS AND THEIR EFFECTS ON NERVE AND MUSCLE	91
J. B. Harris	
✱ 1. Introduction	91
2. Phospholipases	92
3. Venom Phospholipases	95
4. Lipids in Cell Membranes	103

5. Presynaptically Active PLA ₂ Enzymes	104
5.1. The Toxins	104
5.2. Activity at the Neuromuscular Junction	106
5.3. Activity in the Autonomic Nervous System	109
5.4. Activity in the CNS	110
5.5. Activity on Synaptosomes	111
6. The Binding of Toxic PLA ₂ to Neuronal Tissue	114
7. Myotoxic PLA ₂ Enzymes	116
8. Structure-Activity Relationships of the Toxic Phospholipases	119
9. Summary	122
References	123
 4. DENDROTOXINS: SNAKE TOXINS THAT BLOCK POTASSIUM CHANNELS AND FACILITATE NEUROTRANSMITTER RELEASE	 131
Alan L. Harvey and A. J. Anderson	
1. Introduction	131
2. Chemistry and Structure-Activity Relationships	133
2.1. Chemical Features	133
2.2. Structure-Activity Relationships	136
3. Effects on Transmitter Release	140
3.1. Skeletal Muscle Neuromuscular Junctions	140
3.2. Autonomic Nervous System	148
3.3. Sensory Nervous System	149
3.4. Central Nervous System	151
4. Isolation of Target Sites	154
5. Conclusions	158
References	160
 5. STRUCTURE-FUNCTION RELATIONSHIPS OF POSTSYNAPTIC NEUROTOXINS FROM SNAKE VENOMS	 165
Toshiya Endo and Nobuo Tamiya	
1. Introduction	165
2. Sequence	166
2.1. Primary Structure	166
2.2. Invariant Residues	172
3. Conformation	177
3.1. Conformation in Crystals	177
3.1.1. Erabutoxin b (Eb)	177
3.1.2. α -Cobratoxin (α -Cbt)	177
3.1.3. α -Bungarotoxin (α -Bgt)	178
3.2. Conformation in Solution	178
3.2.1. Spectroscopic approaches	178
3.2.2. Differences between the conformations of neurotoxins in crystals and in solution	181
3.3. Dynamic Structure	185
3.4. Maintenance of Toxin Structure	186
3.4.1. Structurally important residues	186
3.4.2. Role of the hydrophobic core	188
4. Interaction with the Receptor	189
4.1. Structure of the Acetylcholine Receptor	189
4.2. Binding Sites of the AChR for Cholinergic Ligands and Neurotoxins	190

4.3.	Functionally Essential Residues of Neurotoxins	195
4.3.1.	Functionally essential residues common to short and long neurotoxins	195
4.3.2.	COOH-terminal tail in long neurotoxins	197
4.4.	Binding Region of Neurotoxins for the Receptor	198
4.5.	Conformational Change in the Neurotoxin and Receptor	202
4.6.	ESR and Fluorescence Analyses to Monitor Neurotoxin-Receptor Interaction	205
4.6.1.	Spin-labeled neurotoxin	205
4.6.2.	Fluorescent-labeled neurotoxin	206
4.6.3.	Stopped-flow fluorescence measurement	207
* 4.7.	Species Differences in the Receptor and Its Interaction with Neurotoxin	208
* 5.	Concluding Remarks	209
	References	210
* 6.	κ -NEUROTOXINS AND α -NEUROTOXINS: EFFECTS ON NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS	223
	Vincent A. Chiappinelli	
1.	Introduction	223
2.	Snake Toxins that Interact with Nicotinic Acetylcholine Receptors	223
* 2.1.	Muscle and Electric Organ Nicotinic Receptors	224
2.1.1.	α -Neurotoxins as probes for nicotinic receptors	224
2.2.	Neuronal Nicotinic Receptors in Vertebrates	225
2.2.1.	Results with α -neurotoxins	225
2.2.2.	Results with κ -neurotoxins	236
2.2.3.	Results with toxins that have phospholipase activity	246
2.3.	Neuronal Nicotinic Receptors in Invertebrates	247
2.3.1.	Molluscs	247
2.3.2.	Arthropods	248
3.	Snake Toxins that Interact with Noncholinergic Receptors	250
3.1.	Vipoxin	250
3.2.	β -RTX	251
* 4.	Conclusions	251
	References	252
7.	THE STRUCTURE AND PHARMACOLOGY OF ELAPID CYTOTOXINS	259
	M. J. Dufton and R. C. Hider	
1.	Introduction	259
2.	Isolation and Purification of Cytotoxins	259
3.	Cytotoxin Sequence Information	260
3.1.	General Classification	260
3.2.	Evolution	261
4.	Cytotoxin Conformation	264
4.1.	X-ray Crystallography	265
4.2.	^1H Nuclear Magnetic Resonance	267
4.3.	Circular Dichroism	268
4.4.	Accessibility of Aromatic Residues	270
5.	Cytotoxin Evolution in Three Dimensions	271
5.1.	Location of Conserved and Variable Areas	271
6.	Mode of Action of Cytotoxins	272
6.1.	Nature of Binding Site	272

6.2. Lipid–Cytotoxin Interactions	273
6.3. Protein or Carbohydrate—Cytotoxin Interactions	276
6.4. Mechanism of Cell Lysis	278
6.5. Cytotoxin-Induced Protein Aggregation	281
6.6. Cytotoxin–Phospholipase Synergism	282
6.7. Interaction of Cytotoxins with Muscle Cells	282
6.7.1. ATP-dependent cation pumps	284
6.7.2. Endogenous phospholipase A ₂	284
6.7.3. Displacement of membrane-bound Ca ²⁺	284
6.7.4. Activation of endogenous Ca ²⁺ channel	284
7. Structure–Activity Analysis	286
7.1. Erythrocyte Lysis	286
7.2. LD ₅₀	286
7.3. Muscle Cell Depolarization	288
7.4. Structure–Activity by Implication from the α -Neurotoxins	292
7.5. Conclusions on Structure and Activity	294
8. Concluding Discussion	294
8.1. Implications of Sequence Composition	295
8.2. Implications of Structure	295
8.3. Implications of Assays	295
8.4. Why Is the Target Obscure?	296
8.5. The Role of Phospholipase A ₂	297
9. Conclusions	297
References	298
8. FASCICULINS, ANTICHOLINESTERASE TOXINS FROM MAMBA VENOMS: BIOCHEMISTRY AND PHARMACOLOGY	303
Carlos Červeňanský, Federico Dajas, Alan L. Harvey, and Evert Karlsson	
1. Introduction	303
2. Isolation of Fasciculins	304
3. Fasciculins and Cholinesterases	304
3.1. Cholinesterases	304
3.1.1. Preparation of samples	304
3.1.2. Assay of cholinesterase activity	306
3.2. Cholinesterase Activity and Fasciculin	306
3.2.1. Inhibition	306
3.2.2. Partial inhibition and reactivation	309
3.2.3. No or very weak effect	310
4. Inhibition of Proteolytic Activity	311
5. Pharmacological Effects of Fasciculins	311
5.1. Neuromuscular Effects	311
5.2. Effects In Vivo	314
5.3. Fasciculin and the CNS	314
6. Structure–Activity Relationship	317
7. Concluding Remarks	318
References	319
9. THE INFLUENCE OF SNAKE VENOM PROTEINS ON BLOOD COAGULATION	323
F. Kornalík	
1. Introduction	323
2. Physiology of Blood Coagulation	324
2.1. Vessel Wall	324

2.2. Thrombocytes	324
2.3. Plasmatic System	326
3. Action of Snake Venom Enzymes on Blood Coagulation	332
3.1. Introduction	332
3.2. Activity of Venom Enzymes In Vitro	334
3.2.1. Action on fibrinogen	334
3.2.2. Action on prothrombin	345
3.2.3. Action on F X	349
3.2.4. Action on F V	351
3.2.5. Action on platelets	352
3.2.6. Anticoagulant action	360
3.3. Use of Snake Venom Enzymes for Diagnostic and Experimental Purposes	363
3.3.1. Russell's viper venom	363
3.3.2. Reptilase®-R	365
3.3.3. Use of batroxobin and ancrod in experiments in vivo	366
3.3.4. Ecarin	367
3.4. Clinical Use of Venom Enzymes	370
3.4.1. Anticoagulant—defibrinating effect	370
3.4.2. Procoagulant hemostatic effect	372
References	375
10. CLONING AND EXPRESSION OF cDNAs ENCODING SNAKE TOXINS	385
Frédéric Ducancel, Christiane Bouchier, Toru Tamiya, Jean-Claude Boulain, and André Ménez	
1. Introduction	385
2. Biosynthesis	385
3. Cloning and Nucleotide Sequencing	386
3.1. Curaremimetic Toxins	386
3.1.1. Purification of messenger RNAs	386
3.1.2. Preparation of double-stranded cDNAs	388
3.1.3. Fractionation of cDNAs	388
3.1.4. Construction of cDNA library	389
3.1.5. Nucleotide sequences of cDNAs	389
3.1.6. Protein sequences of precursors as deduced from cDNA sequencing	390
3.1.7. Nucleotide sequence of genomic DNA	391
3.2. Other Toxins Structurally Related to Curaremimetic Toxins	391
3.2.1. Neuronal toxins	392
3.2.2. Muscarinic toxins	392
3.2.3. Fasciculins	392
3.2.4. "Synergistic-type" proteins	394
3.2.5. Conclusion	394
3.3. Myotoxins	394
3.4. Proteins with Phospholipase A ₂ Structure (PLA ₂)	395
3.4.1. cDNAs encoding sea snake PLA ₂	395
3.4.2. cDNAs encoding land snake PLA ₂	396
3.4.3. Comparison of cDNAs encoding PLA ₂ from different snake families	401
3.4.4. Comparison of precursors of PLA ₂ from snakes and mammals	401

4. Expression of RNAs and/or cDNAs	403
4.1. Use of In Vitro Translation Systems	403
4.2. Injection of mRNAs into Frog Oocytes	405
4.3. Production of Toxins in Bacteria	405
4.3.1. Expression vector construction	405
4.3.2. Production and purification of the hybrid	407
4.3.3. Biological properties of the hybrid	407
4.3.4. Properties of antibodies directed against hybrid protein	408
4.3.5. Properties of a recombinant curare-mimetic toxin	408
4.3.6. Conclusion	408
5. Nontoxic Proteins of Snake Venoms	408
5.1. Batroxobin	408
5.2. Cobra Nerve Growth Factor	409
References	412
11. SARAFOTOXINS: A NEW GROUP OF CARDIOTOXIC PEPTIDES FROM THE VENOM OF <i>ATRACTASPIS</i>	415
A. Bdolah, Z. Wollberg, and E. Kochva	
1. Introduction	415
2. Chemical Features	416
3. Lethality	417
4. Cardiovascular Effects	417
4.1. ECG in Mice	417
4.2. Isolated Heart Preparations	418
4.3. Vasoconstrictor Effects in Isolated Aorta	419
5. Cellular Target Sites	420
6. Comparison Between Sarafotoxins and Endothelins	421
References	422
APPENDIX: AMINO ACID SEQUENCES AND TOXICITIES OF SNAKE VENOM COMPONENTS	425
Dietrich Mebs and Ina Claus	
INDEX	449